WebIn patients with mechanical heart valves, use of direct oral anticoagulants (DOACs) is currently contraindicated, and their use in patients with bioprosthetic heart valves is off-label. 1,2 We sought to determine the … WebA bioprosthesis was our patient population with a high rate of valve reopera- explanted in 227 patients, with a mean interval of 94.2 6 tions. Since then, 1,049 prostheses have been implanted 36.9 months.
Safety and Use of Anticoagulation After Aortic Valve Replacement With
WebThrombosis of a prosthetic valve is potentially life-threatening, resulting in hemodynamically severe stenosis or regurgitation. "Thrombotic risk is related to the type of valve, position of the valve and adequacy of anticoagulation," according to Vuyisile T. Nkomo, M.D., M.P.H., director of the Valvular Heart Disease Clinic at Mayo Clinic in ... sictom arbois
Update in Bioprosthetic Valve Tissue Technology
WebBackground: Data on the use of direct oral anticoagulants in the setting of bioprosthetic valve replacements is limited.Objective: The purpose of this study was to describe outcomes among patients who underwent a bioprosthetic valve replacement and were subsequently prescribed apixaban.Methods: A retrospective cohort study was completed for inpatients … WebBackground: The American College of Cardiology guidelines recommend 3 months of anticoagulation after replacement of the aortic valve with a bioprosthesis. However, there remains great variability in the current clinical practice and conflicting results from clinical studies. To assist clinical decision making, we pooled the existing evidence to assess … WebDec 17, 2024 · Among patients with atrial fibrillation and native heart valve disease other than rheumatic mitral stenosis, or among patients with atrial fibrillation and a bioprosthesis >3 months after valve replacement, a non–vitamin K oral anticoagulant (NOAC) is an effective alternative to anticoagulation with a vitamin K antagonist (VKA); among these ... sictom 91